I.     INTRODUCTION                                                                   1
II.    BACKGROUND                                                                     2
III.   OVERVIEW     OF  FDA  RISK  ASSESSMENTâ€”PRE-        AND  POSTMARKET             3
A.   Premarket Risk Assessment                                                      3
B.   Postmarket Risk Assessment                                                     5
IV.    CRITERIA   FOR   DETERMINING      WHETHER     NEW   RISK  INFORMATION      IS
APPROPRIATE     FOR   DISTRIBUTION     TO  HEALTH    CARE   PROFESSIONALS
AND  HEALTH    CARE   ENTITIES                                                 6
